Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct;15(10):859–869. doi: 10.1089/dia.2013.0013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2013, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 2. — Comparisons of treatment efficacy in the four treatment groups. ALA, α-lipoic acid; MET, metformin; TZD, thiazolidinedione. (a) Insulin dosages and days to target during continuous subcutaneous insulin infusion (CSII) treatment period. (b) Changes from baseline after CSII suspension and at month 3 in body weight and waist circumference. (c) Changes from baseline after CSII suspension and at month 3 in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG). (d) Proportions of patients achieving HbA1c <7%, 6.5%, and 6% in each treatment group. (e) Changes from baseline after CSII suspension in lipid profile. HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NEFA, nonesterified fatty acid. (f) Changes from baseline after CSII suspension and at month 3 in homeostasis model assessment of β-cell function (HomaB), acute insulin response (AIR), and proinsulin to insulin ratio. (g) Changes from baseline after CSII suspension in homeostasis model assessment of insulin resistance (HomaIR) and intramyocellular lipid (IMCL) and malondialdehyde (MDA) levels.

FIG. 2. — Comparisons of treatment efficacy in the four treatment groups. ALA, α-lipoic acid; MET, metformin; TZD, thiazolidinedione. (a) Insulin dosages and days to target during continuous subcutaneous insulin infusion (CSII) treatment period. (b) Changes from baseline after CSII suspension and at month 3 in body weight and waist circumference. (c) Changes from baseline after CSII suspension and at month 3 in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG). (d) Proportions of patients achieving HbA1c <7%, 6.5%, and 6% in each treatment group. (e) Changes from baseline after CSII suspension in lipid profile. HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NEFA, nonesterified fatty acid. (f) Changes from baseline after CSII suspension and at month 3 in homeostasis model assessment of β-cell function (HomaB), acute insulin response (AIR), and proinsulin to insulin ratio. (g) Changes from baseline after CSII suspension in homeostasis model assessment of insulin resistance (HomaIR) and intramyocellular lipid (IMCL) and malondialdehyde (MDA) levels.